EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Macrocycles for Conventionally Druggable Targets: Lessons from Macrocyclic Kinase Inhibitors

Lauren A Viarengo-Baker iD, Adrian Whitty iD

Journal of Medicinal Chemistry · 14.08.2025 · 68 (15) · 15260-15284

DOI: 10.1021/acs.jmedchem.4c02886 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 31.07.2025. Verfasst von Lauren A Viarengo-Baker und 1 weiteren Autor:innen. Beteiligte Einrichtung: Relay Therapeutics, 399 Binney Street, Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Macrocyclic Compounds. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 76 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrocycles are emerging as a prominent modality in drug discovery, including for conventionally druggable targets for which simpler, acyclic ligands are readily discoverable. Given the additional synthetic challenges associated with macrocyclic chemotypes, we address what benefits macrocycles provided for these highly druggable targets. To do this, we examine the effects of macrocyclization on inhibitors of highly druggable kinase targets. For each example, we isolate closely matched acyclic/macrocyclic compound pairs, allowing us to pinpoint the effects of macrocyclization on binding affinity, selectivity, and ADME properties absent confounding factors. Our findings show that while the impact of macrocyclization on potency is variable, a profound effect on selectivity is common. Macrocyclization can also bring benefits for membrane permeability, efflux ratio, blood-brain barrier penetrance, and metabolic stability. These findings lead us to propose specific circumstances in which a drug discoverer targeting kinases or other conventionally druggable target classes should consider a macrocycle approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsMacrocyclic CompoundsHumansDrug DiscoveryStructure-Activity RelationshipAnimalsBlood-Brain Barrier

Substanzen

Protein Kinase InhibitorsMacrocyclic Compounds

Autor:innen und Institutionen

  • Relay Therapeutics, 399 Binney Street, Cambridge, Massachusetts 02139, United States.

ORCID-Profile: Lauren A Viarengo-Baker, Adrian Whitty

Zitieren

APA

Viarengo-Baker, L. A., & Whitty, A. (2025). Macrocycles for Conventionally Druggable Targets: Lessons from Macrocyclic Kinase Inhibitors. Journal of Medicinal Chemistry, 68(15), 15260-15284. https://doi.org/10.1021/acs.jmedchem.4c02886

Vancouver

Viarengo-Baker LA, Whitty A. Macrocycles for Conventionally Druggable Targets: Lessons from Macrocyclic Kinase Inhibitors. Journal of Medicinal Chemistry. 2025;68(15):15260-15284. doi:10.1021/acs.jmedchem.4c02886

BibTeX
@article{ViarengoBaker2025,
  author = {Viarengo-Baker, Lauren A and Whitty, Adrian},
  title = {Macrocycles for Conventionally Druggable Targets: Lessons from Macrocyclic Kinase Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {15},
  pages = {15260--15284},
  doi = {10.1021/acs.jmedchem.4c02886}
}
Kostenlos starten →